Medifast, Inc. (MED) , a leading weight management and healthy living products company, has faced a tough period, with its stock declining significantly by 24.7% over the past three months. This decline is notably steeper compared with the industry's decline of 5.4% and the Zacks Food - Miscellaneous sector's marginal decline of 1% in the same timeframe. The current stock price is down 79% from its 52-week high of $92.13, highlighting the severity of the downturn. Medifast's stock is trading below its 50-da ...

Core Insights - Medifast, Inc. reported a decline in both earnings and net revenues for Q2 2024, but exceeded Zacks Consensus Estimates for both metrics [1][3][4] - The company is strategically adjusting its operations to adapt to the evolving weight loss industry, including enhanced marketing efforts and a partnership with LifeMD [1][2] Financial Performance - Adjusted earnings per share were 92 cents, down from $2.77 year-over-year, surpassing the Zacks Consensus Estimate of 36 cents [3] - Net revenues totaled $168.9 million, a 43.1% decline year-over-year, primarily due to a decrease in active earning OPTAVIA Coaches and reduced productivity per Coach [3][4] - The average revenue per active earning OPTAVIA Coach decreased by 10.9% to $4,972 from $5,578 [3] - The total number of active earning OPTAVIA Coaches fell by 36.2% to 33,900 from 53,100 year-over-year [4] Profitability Metrics - Adjusted gross profit was $126 million, down 40.2% year-over-year, with a gross profit margin of 74.8%, an increase of 370 basis points year-over-year [4] - Adjusted selling, general and administrative expenses (SG&A) decreased by 33.8% year-over-year to $113.8 million, but as a percentage of revenues, SG&A expenses increased by 940 basis points to 67.5% [5][6] Operational Insights - Adjusted income from operations declined by 68.4% to $12.2 million, with an adjusted operating margin of 7.3%, down 580 basis points year-over-year [7] - The company ended the quarter with cash, cash equivalents, and investments of $165.3 million, with no interest-bearing debt and total shareholders' equity of $205.3 million [8] Future Guidance - Management expects revenues for Q3 to be in the range of $125-$145 million, with projected loss per share between 5-70 cents [9] - The earnings guidance excludes costs related to the partnership with LifeMD and any market price changes of the company's LifeMD investment [9]

Medifast, Inc. (MED) is likely to register a top and bottom-line decline when it reports second-quarter 2024 earnings on Aug 5. The Zacks Consensus Estimate for revenues is pegged at $160.4 million, which indicates a 45.8% slump from the year-ago period. The consensus mark for earnings has remained unchanged in the past 30 days at 36 cents per share, which suggests a substantial decline of 87% from the year-ago quarter's figure. MED has a trailing four-quarter earnings surprise of 48.7%, on average. Factors ...

The Zacks Consensus Estimate for 2024 earnings per share has declined from $2.80 to 94 cents in the past 30 days. Additionally, this Zacks Rank #5 (Strong Sell) stock has slumped 44.1% in the past three months compared with the industry's decline of 4.3%. Medifast has been encountering difficulties in attracting customers, primarily because of a range of macroeconomic elements, such as the increasing popularity of GLP-1 medications, the rapidly changing economy and shifts in social media algorithms. Undoubt ...

Medifast, Inc. (MED) delivered first-quarter 2024 results, with the top and bottom lines declining year over year. While the bottom line missed the Zacks Consensus Estimate, the top line exceeded the same.Medifast is strategically adjusting its operations to meet the changing demands of the weight-loss industry. This involves expanding its customer outreach through enhanced marketing efforts and entering the medically-supported weight-loss domain in partnership with LifeMD.These steps are designed to increa ...

Medifast (NYSE:MED) stock is falling on Tuesday after the weight loss company released its earnings report for the first quarter of 2024.The bad news for MED stock comes from its adjusted earnings per share of 66 cents. That’s well below Wall Street’s estimate of 80 cents for the quarter. It’s also much worse than the $3.67 per share reported in the same period of the year prior.Medifast also reported revenue of $174.74 million during Q1. That’s better than the $173.45 million analysts were expecting. Howev ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to ________. Commission File Number: 001-31573 Medifast, Inc. (Exact name of registrant as specified in its charter) | Delaware | 13-3714405 | ...

BALTIMORE – (BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024. First Quarter 2024 "Fast paced medical innovation is providing greater access to medical weight loss solutions than ever before. We are transforming our OPTAVIA offer to include comprehensive support for consumers who wish to use GLP-1 medical weight loss solutions on their individual jou ...

Medifast, Inc. (MED) is on track to transition into a diversified health and wellness company. The company continues to invest in customer acquisition and experience to sustain long-term growth. Management is progressing well with the 'Fuel for the Future' program. However, MED is not immune to the volatile macroeconomic environment with inflation.Let’s discuss this in detail.Growth Efforts in PlaceMedifast regularly adapts to shifting consumer behavior to maintain its relevance. To this end, management is ...

Medifast (MED) shares ended the last trading session 5.9% higher at $36.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 32.8% loss over the past four weeks.Medifast’s shares have been gaining on optimism surrounding efforts to broaden its presence in the expansive health and wellness market. The company is foraying into popular medically supported weight management and sports nutrition segments. Medifast’s inve ...